SCHEMBL5752080

SCHEMBL5752080

Clc1ccc(C2CCN(Cc3ccc4[nH]ccc4c3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
MCHR1 Q99705 3/20 0.53
SSTR5 P35346 1/20 0.48
F7 P08709 1/20 0.48
LTA4H P09960 1/20 0.48
F3 P13726 1/20 0.48
AHR P35869 1/20 0.48
NR4A2 P43354 1/20 0.48
DRD2 P14416 4/20 0.47
OPRM1 P35372 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46
ACHE P22303 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
HTR4 Q13639 1/20 0.46
FAAH O00519 1/20 0.46
DRD4 P21917 4/20 0.46
DRD3 P35462 3/20 0.46
PARP1 P09874 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7078098 0.88 MAPT (0.57) MEN1KMT2AMCHR1SSTR5DRD2
SCHEMBL5753239 0.88 SSTR5 (0.58) MCHR1SSTR5AHRDRD2ACHE
SCHEMBL5751430 0.88 DRD4 (0.52) MEN1KMT2AMCHR1SSTR5DRD2
SCHEMBL26134148 0.80 FAAH (0.55) MCHR1SSTR5ACHESIGMAR1HTR4
SCHEMBL5754611 0.80 MAPT (0.57) MCHR1F7LTA4HF3AHR
SCHEMBL5753083 0.79 DRD2 (0.53) MEN1KMT2AMCHR1DRD2ACHE
SCHEMBL5755013 0.79 MCHR1 (0.50) MEN1KMT2AMCHR1SSTR5AHR
SCHEMBL15642646 0.77 SIGMAR1 (0.54) SSTR5DRD2OPRM1OPRK1OPRL1
SCHEMBL13293706 0.76 FAAH (0.55) LTA4HSIGMAR1FAAHDRD4ALDH1A1
SCHEMBL22584711 0.75 LTA4H (0.63) MCHR1LTA4HACHESIGMAR1HTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105543-B2 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2006-09-12 US claimed
EP-1309586-B1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS LUNDBECK & CO AS H (DK) 2006-03-22 EP claimed
US-20030166665-A1 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2003-09-04 US claimed
US-7105543-B2 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2006-09-12 US disclosed
EP-1309586-B1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS LUNDBECK & CO AS H (DK) 2006-03-22 EP disclosed
US-20060004022-A1 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2006-01-05 US disclosed
US-6958338-B2 4-,5-,6-and 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2005-10-25 US disclosed
US-20030166665-A1 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders H. LUNDBECK A/S (DK) 2003-09-04 US disclosed
EP-1309586-A1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2003-05-14 EP disclosed
WO-2002016349-A1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004022-A1 4-, 5-, 6- And 7-indole derivatives useful for the treatment of CNS disorders HTR3C, SLC6A3, HTR6 MEN1 2188/4885KMT2A 1481/4885MCHR1 95/4885
US-20030166665-A1 4-,5-,6-And 7-indole derivatives useful for the treatment of CNS disorders HTR3C, HTR6, SLC6A3 MEN1 2805/4885KMT2A 1049/4885MCHR1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.